Relapsed/Refractory Multiple Myeloma: Treatment Strategies & Emerging Therapies

Relapsed/refractory multiple myeloma (RRMM) defines disease that has returned after prior response (relapsed) or never adequately responded to frontline therapy (refractory). Management is highly individualized, balancing depth of response, toxicity, and quality of life.

Core Treatment Principles

  • Switch mechanisms: Avoid reusing the same drug class if refractory.
  • Triplet/quadruplet regimens are standard—combining agents with non-overlapping toxicities and synergistic mechanisms.
  • Sequencing matters: Preserve future options; consider clinical trials at every decision point.
  • Patient factors: Age, fitness, comorbidities, prior toxicities, cytogenetics (high-risk: del17p, t(4;14), t(14;16), gain 1q).

Major Drug Classes & Key Agents

Proteasome Inhibitors (PIs)

  • Bortezomib (Velcade): First-in-class; SC formulation reduces peripheral neuropathy.
  • Carfilzomib (Kyprolis): Irreversible, epoxyketone; cardiac monitoring required; used in later lines.
  • Ixazomib (Ninlaro): Oral; convenient for maintenance/combinations.

Immunomodulatory Drugs (IMiDs)

  • Lenalidomide (Revlimid): Backbone of frontline & maintenance; reused in RRMM combos if not refractory.
  • Pomalidomide (Pomalyst): Active in lenalidomide-refractory disease; potent with dexamethasone.

Anti-CD38 Monoclonal Antibodies

  • Daratumumab (Darzalex): SC formulation; cornerstone of modern RRMM regimens (Dara-Pd, Dara-Kd, Dara-Rd).
  • Isatuximab (Sarclisa): Combined with Pd or Kd.

Anti-SLAMF7 Antibody

  • Elotuzumab (Empliciti): Combined with Rd or Pd.

Stem Cell Transplant (SCT)

  • Autologous SCT at first relapse if not done upfront (or as consolidation after re-induction).
  • Allogeneic SCT: investigational; high transplant-related mortality.

Novel & Approved Therapies for Heavily Pretreated RRMM (≥4 Prior Lines)

  • CAR T-cell therapy: Ciltacabtagene autoleucel (Carvykti), Idecabtagene vicleucel (Abecma) — BCMA-targeted.
  • Bispecific antibodies (TCEs): Teclistamab (Tecvayli), Elranatamab (Elrexfio) — BCMA × CD3; subcutaneous, stepwise dosing for CRS mitigation.
  • SINE (XPO1 inhibitor): Selinexor (Xpovio) + dexamethasone or bortezomib/dex.
  • BCMA-ADC: Belantamab mafodotin (Blenrep) — accelerated approval withdrawn; under investigation.

Essential Supportive Care

  • Bone: bisphosphonates/denosumab for lytic lesions.
  • Infection: antiviral prophylaxis; IVIG if IgG <400 mg/dL.
  • Anemia: ESAs or transfusions.
  • Renal: hydration, avoid nephrotoxins, adjust dosing.
  • Neuropathy/pain/psychosocial: multidisciplinary.

Monitoring & Goals

  • Monthly: SPEP/UPEP, FLC, CBC, CMP, imaging (PET/CT or MRI) per schedule.
  • Target: ≥VGPR (very good partial response) → deeper = longer PFS.
  • Balance: disease control vs. cumulative toxicity vs. patient priorities.

RRMM is a chronic, treatable disease. The expanding arsenal—especially immunotherapies—offers multiple lines of effective therapy. Clinical trial enrollment should be discussed at every juncture.

Multiple Sclerosis - Related Articles